Publications

2026 | Cancer

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

Authors:

Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson LD, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Diaz A, Dima D, Efebera YA, Gowda L, Hansen DK, Hashmi H, Landau HJ, Lekakis L, Mirza AS, Narra R, Patel K, Rosko AE, Schroeder M, Sidana S, Usmani S, Pasquini MC, Nishihori T, Akhtar OS, Mohan M

2026 | Journal of Clinical Oncology

Erratum: Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation.

Authors:

Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, Lekrone E, Wu J, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis R, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Madbouly A, Maiers M, Fingerson S, Cook R, Ballen K, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Jimenez Jimenez AM

2026 | British Journal of Haematology

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Authors:

Awan FT, Liu R, Huang HH, Bye M, Ahn KW, Krigsfeld G, Raz A, Wolfe H, Hamadani M

2026 | Blood Cancer Journal

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Authors:

Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson LD Jr., Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK

2026 | American Journal of Hematology

Phase II study of posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort.

Authors:

Schaffer BC, Al Malki MM, Jimenez AMJ, Stanek J, Bo-Subait S, Logan BR, Kou J, Leckrone E, Stefanski HE, Spellman SR, Malmberg C, Askar M, Cusatis R, Modi D, Khimani F, Hamadani M, Maiers M, Cook R, Ballen K, Bolaños-Meade J, Rao U, Milner J, Abboud R, Jamieson K, Carrum G, Dholaria B, Hogan WJ, Reshef R, Kosuri S, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Auletta JJ, Shaw BE, Devine SM, Gooptu M

2026 | Blood Advances

Interpreting cord blood transplant outcomes in BMT CTN 1702.

Authors:

Das, R, Scaradavou, A, Barker, J, Fingrut, WB

2026 | Blood Advances

Patient-reported outcomes in clinical trials: Lessons from the Blood and Marrow Transplant Clinical Trials Network.

Authors:

Hamilton, BK, Lee, CJ, Mattila, D, El-Jawahri, A, Cusatis, R, Brazauskas, R, Sung, AD, Phelan, R, Horowitz, MM, Lee, SJ

2026 | Human Immunology

Allele and haplotype frequencies in high-resolution typing of human leukocyte antigen -A,-B, -C, -DRB1, and -DQB1 in 263,542 Thai voluntary stem cell donors.

Authors:

Khanuntong S, Tupmongkol T, Phiancharoen S, Tiyapan A, Kupatawintu P, Maiers M, Chiewslip P

2026 | Blood Advances

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Authors:

Jimenez Jimenez AM, Stanek J, Logan BR, Lekrone E, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis RN, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Maiers M, Bo-Subait S, Bolaños-Meade J, Rao U, Milner J, Abboud R, Jamieson KJ, Carrum G, Dholaria B, Hogan WJ, Reshef R, Kosuri S, Cook RJ, Ballen K, Loren AW, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Al Malki MM

2026 | Blood Advances

Donor-specific transplant outcomes from BMT CTN 1702: A multicenter prospective biologic assignment trial.

Authors:

Bashey, A, Logan, BR, Hill, L, Symons, H, Farhadfar, N, Grunwald, MR, Pidala, J, Dehn, JG, Brunstein, C, Arai, S, Leifer, E, He, N, Shaw, BE, Juckett, M, Devine, S, Uberti, J, Westervelt, P, Srour, SA, Pusic, I, Vasu, S, Hayes-Lattin, B, Ciurea, SO, Horowitz, MM, Lee, SJ, Hogan, WJ

2026 | Transplantation and Cellular Therapy

Challenges with expansion of cell and gene therapy: A call for system-level action.

Authors:

Auletta JJ, Urbano-Ispizua A, Maziarz RT, Shaw BE, Sureda A, Vasu S, Porter DL

2026 | Human Immunology

GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches.

Authors:

Kirshenboim O, Kabya A, Yehezkel-Imra R, Tshuva Y, Maiers M, Gragert L, Bashyal P, Israeli S, Louzoun Y

2026 | Transplantation and Cellular Therapy

Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following axicabtagene ciloleucel or brexucabtagene autoleucel chimeric antigen receptor T-cell therapy: Center for International Blood and Marrow Transplant Research data.

Authors:

Frigault MJ, Maziarz RT, Amoloja T, Burke L, Bhatt V, Moskop A, Pasquini M, DiPersio JF

2026 | Journal of human immunity

Classical HLA allele and haplotype frequency estimates in US populations.

Authors:

Gragert L, Madbouly A, Bashyal P, Wadsworth K, Kempenich J, Bolon YT, Maiers M

2026 | Blood Advances

Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial

Authors:

Auletta JJ, Stanek J, Bo-Subait S, Al Malki MM, Cook RJ, Gooptu M, Shaffer BC, Jimenez Jimenez AM, Modi D, Hill JA, Huppler AR, Kou J, Cusatis RN, Broglie L, Shaw BE, Stefanski HE, Spellman SR, Devine SM

2026 | Journal of human immunity

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Authors:

Winestone LE, Logan BR, Liu X, Williams O, Dunn EA, Thakar MS, Kidd SA, Mousallem T, Dorsey MJ, O'Reilly RJ, Kapoor N, Forbes Satter L, Kapadia M, Jyonouchi SC, Chandra S, Ebens CL, Chellapandian D, Chaudhury S, Chen K, Dávila Saldaña BJ, Rayes A, Quigg TC, Chandrakasan S, Bednarski JJ, DeSantes KB, Teira P, Gillio AP, Eissa H, Knutsen AP, Aquino VM, Shereck EB, Moore TB, Caywood EH, Vander Lugt MT, Rozmus J, Broglie L, Yu LC, Shah AJ, Joshi AY, Buckley RH, Dara J, Oved JH, Abdel Azim H, Martinez CA, Prockop S, Sullivan KE, Bleesing JJ, Keller MD, Madden LM, Parikh S, Shenoy S, Seroogy CM, Rubin T, Licata J, Andolina JR, Kohn DB, Burroughs L, Leiding JW, Marsh RA, Notarangelo LD, Pai SY, Torgerson TR, Pulsipher MA, Heimall J, Cuvelier GDE, Griffith LM, Puck JM, Dvorak CC, Cowan MJ, Haddad E

2026 | Biometrics

Group sequential clinical trial designs for composite endpoints incorporating recurrent and terminal events.

Authors:

Lian, Q, Woo Ahn, K, Kim, S, Logan, BR, Solh, M, Martens, MJ

2026 | Blood Reviews

What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.

Authors:

Hong S, Espinoza-Gutarra MR, Shah R, Demartino P, Davies SM, Nemecek E, Howard D, DeSalvo AM, Meyer CL, Majhail NS, Preussler JM, Hall AG, Arteaga AG, Auletta JJ, Khera N

2026 | JCO Oncology Practice

Access challenges in allogeneic hematopoietic cell transplant: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need.

Authors:

Waters SE, Meyer CL, Preussler JM, Sennaka MKS, Auletta JJ, Borzekowski DLG

2026 | Transplantation and Cellular Therapy

Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis.

Authors:

Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, 13. Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, 28. Akhtar OS, Auletta JJ, Huppler AR, Abid MB